This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
by Zacks Equity Research
BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.
BDXPositive Net Change ISRGPositive Net Change CAHNegative Net Change SOLVPositive Net Change
medical medical-devices
GEHC Forms 7-Year Care Alliance to Advance URMC Imaging & Monitoring
by Zacks Equity Research
GE HealthCare's seven-year alliance with URMC advances imaging, precision medicine and system-wide monitoring upgrades across UR Medicine.
BSXNegative Net Change ISRGPositive Net Change MEDPPositive Net Change GEHCPositive Net Change
medical medical-devices
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
by Zacks Equity Research
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
ANIPNegative Net Change CRMDNegative Net Change ARQTPositive Net Change ABSINegative Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
by Zacks Equity Research
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
ANIPNegative Net Change CRMDNegative Net Change CAPRPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali Enters Into a $275M Funding Deal With Royalty Pharma
by Ekta Bagri
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
BIIBNegative Net Change RPRXPositive Net Change DNLINegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run. Stocks like KSS, HRTG, MD and NEM are seeing price strength, and the momentum is likely to continue.
KSSPositive Net Change NEMNegative Net Change MDNegative Net Change HRTGNegative Net Change
basic-materials finance medical retail
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
by Ekta Bagri
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
NVSNegative Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
by Urmimala Biswas
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
EXASNegative Net Change GHNegative Net Change TEMPositive Net Change
healthcare medical medical-devices oncology-screening
COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises
by Zacks Equity Research
COO jumps after Q4 earnings and sales top estimates, powered by rising MyDay demand and strong MiSight momentum.
ISRGPositive Net Change COOPositive Net Change MEDPPositive Net Change SGHTNegative Net Change
earnings medical medical-devices
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.
ISRGPositive Net Change INGNNegative Net Change MEDPPositive Net Change SGHTNegative Net Change
medical medical-devices
MDT Stock Set to Benefit From the FDA Clearance of Hugo RAS System
by Zacks Equity Research
Medtronic gains from the FDA clearance of its Hugo RAS system, expanding U.S. access to robotic-assisted urologic surgery.
MDTNegative Net Change OMCLPositive Net Change ILMNPositive Net Change BTSGPositive Net Change
medical medical-devices
Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves
by Sridatri Sarkar
TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition.
MEDPositive Net Change HIMSNegative Net Change TEMPositive Net Change
medical
Reasons to Add Omnicell Stock to Your Portfolio Right Now
by Zacks Equity Research
OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition.
CAHNegative Net Change OMCLPositive Net Change PAHCNegative Net Change BTSGPositive Net Change
medical
Do Options Traders Know Something About Owens & Minor Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor stock based on the movements in the options market lately.
OMIPositive Net Change
medical
The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley
by Zacks Equity Research
HSBC, Abbott, Shell and Oak Valley feature in the latest Zacks Analyst Blog as analysts highlight operational resilience, strategic pivots and industry-specific challenges.
ABTNegative Net Change HSBCNegative Net Change OVLYNegative Net Change SHELNegative Net Change
finance medical oil-energy
Zacks.com featured highlights include Plains GP, Edison International, TD SYNNEX, CONMED and PG&E
by Zacks Equity Research
Plains GP, Edison International, TD SYNNEX, CONMED and PG&E stand out for value as low EV-to-EBITDA ratios spotlight potential opportunities.
EIXPositive Net Change PCGNegative Net Change CNMDNegative Net Change SNXPositive Net Change PAGPNegative Net Change
computers medical oil-energy utilities
Top Analyst Reports for HSBC, Abbott & Shell
by Mark Vickery
HSBC's Asia pivot, Abbott's device momentum and Shell's resilient Q3 results headline today's standout analyst reports.
EXCNegative Net Change ABTNegative Net Change PHMNegative Net Change HSBCNegative Net Change OVLYNegative Net Change UIPositive Net Change SHELNegative Net Change
finance medical oil-energy
Implied Volatility Surging for Eton Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ETON stock based on the movements in the options market lately.
ETONNegative Net Change
medical
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
by Zacks Equity Research
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
BCRXNegative Net Change IONSNegative Net Change KALVPositive Net Change PHVSNegative Net Change
biotechs medical
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
by Zacks Equity Research
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
ISRGPositive Net Change IDXXNegative Net Change HIMSNegative Net Change SOLVPositive Net Change
medical medical-devices
IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?
by Zacks Equity Research
IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.
BSXNegative Net Change MDTNegative Net Change IDXXNegative Net Change GMEDPositive Net Change
medical
HealthEquity Stock Gains as Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY stock gains post Q3 results as earnings and revenue top estimates, supported by rising HSAs and stronger margins.
BSXNegative Net Change ISRGPositive Net Change HQYNegative Net Change MEDPPositive Net Change
earnings medical medical-devices
GEHC and Mayo Clinic Launch GEMINI-RT to Aid Personalized Cancer Care
by Zacks Equity Research
GE HealthCare and Mayo Clinic unveil GEMINI-RT, which is likely to blend imaging, AI and monitoring to advance personalized cancer care.
BSXNegative Net Change ISRGPositive Net Change MEDPPositive Net Change GEHCPositive Net Change
medical medical-devices
ImmuCell's Two-Product Edge in Cattle Health Fuels Growth
by Urbashi Dutta
ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.
ICCCPositive Net Change
medical
BMY Gains on News of Continuation of Alzheimer's Disease Study
by Zacks Equity Research
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
BMYPositive Net Change FOLDNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals